Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single ascending dose study of paltusotine in healthy volunteers
NL-OMON51860Phase 1Active, not recruiting
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of paltusotine in acromegaly and apudoma (NET) (3 cohorts), sponsored by Crinetics Pharmaceuticals. Primary endpoint: Safety and tolerability. Started Jan 2022; status: active, not recruiting.
02
Drugs
paltusotine
03
Conditions
acromegalyapudoma (NET)
Beyond the preview
Go deeper on NL-OMON51860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51860.